Program
IVPF-07328948
A development code. Also written as “IV [14C]PF-07328948”.
In Pfizer’s pipeline, Branched chain ketoacid dehydrogenase kinase (BDK) inhibitor
. Its studies are led by Pfizer.
Furthest: phase 1, since Mar 27, 20261 company-led study, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 10 open or running | phase 1since Mar 27, 2026 | Mar 27, 2026 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 27, 2026First study: phase 1 study in HealthyFirst studyNCT07508228 · 8 enrolled · United States
TargetBeta
“Branched chain ketoacid dehydrogenase kinase (BDK) inhibitor”the company's pipeline, read by Claude · source
Other programs on BCKDK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| PF-07328948 | Pfizer | phase 2 | 8 |
| ORALPF-07328948 | Pfizer | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07508228Healthy · United States | 1 | Completed | Jul 10, 2026 | 8 |
How it is read
Names in the registry
- “IV [14C]PF-07328948”, 1 entry
Codes read as this program: IVPF07328948.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.